Portside Wealth Group LLC Has $663,000 Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Portside Wealth Group LLC lifted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 631 shares of the biopharmaceutical company’s stock after buying an additional 32 shares during the quarter. Portside Wealth Group LLC’s holdings in Regeneron Pharmaceuticals were worth $663,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. West Paces Advisors Inc. boosted its stake in Regeneron Pharmaceuticals by 575.0% during the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 23 shares in the last quarter. Crewe Advisors LLC bought a new position in Regeneron Pharmaceuticals during the first quarter worth $28,000. MCF Advisors LLC boosted its stake in Regeneron Pharmaceuticals by 50.0% during the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 12 shares in the last quarter. Lynx Investment Advisory bought a new position in Regeneron Pharmaceuticals during the second quarter worth $33,000. Finally, Criterion Capital Advisors LLC bought a new position in Regeneron Pharmaceuticals during the fourth quarter worth $37,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN traded up $3.98 during trading hours on Friday, reaching $1,179.31. 564,438 shares of the company were exchanged, compared to its average volume of 474,058. Regeneron Pharmaceuticals, Inc. has a 1 year low of $769.19 and a 1 year high of $1,185.09. The business’s 50 day simple moving average is $1,070.90 and its 200-day simple moving average is $995.11. The company has a quick ratio of 4.62, a current ratio of 5.44 and a debt-to-equity ratio of 0.10. The stock has a market capitalization of $129.94 billion, a P/E ratio of 34.84, a P/E/G ratio of 2.99 and a beta of 0.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The business had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.38 billion. During the same quarter last year, the company posted $8.79 earnings per share. The firm’s quarterly revenue was up 12.3% compared to the same quarter last year. On average, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.8 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Leonard S. Schleifer sold 9,064 shares of Regeneron Pharmaceuticals stock in a transaction dated Tuesday, June 11th. The shares were sold at an average price of $1,015.43, for a total value of $9,203,857.52. Following the completion of the transaction, the chief executive officer now owns 55,134 shares in the company, valued at $55,984,717.62. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Leonard S. Schleifer sold 9,064 shares of Regeneron Pharmaceuticals stock in a transaction dated Tuesday, June 11th. The shares were sold at an average price of $1,015.43, for a total value of $9,203,857.52. Following the completion of the transaction, the chief executive officer now owns 55,134 shares in the company, valued at $55,984,717.62. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Jason Pitofsky sold 487 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the completion of the transaction, the vice president now owns 4,204 shares of the company’s stock, valued at approximately $4,498,280. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 17,731 shares of company stock worth $18,230,142. Insiders own 7.48% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently issued reports on REGN shares. Piper Sandler increased their target price on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,166.00 and gave the stock an “overweight” rating in a research note on Friday, July 19th. Truist Financial reaffirmed a “buy” rating and issued a $1,200.00 price objective (up from $1,135.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, August 2nd. StockNews.com lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Friday. Guggenheim raised their price objective on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. Finally, TD Cowen raised their price objective on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $1,097.05.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.